Nektar Therapeutics
NASDAQ:NKTR
Nektar Therapeutics
Operating Income
Nektar Therapeutics
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Nektar Therapeutics
NASDAQ:NKTR
|
Operating Income
-$135.2m
|
CAGR 3-Years
29%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
|
Johnson & Johnson
NYSE:JNJ
|
Operating Income
$23.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Income
$10.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
7%
|
CAGR 10-Years
13%
|
|
Pfizer Inc
NYSE:PFE
|
Operating Income
$13.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-3%
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Income
$4.1B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-7%
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Income
$10.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
6%
|
See Also
What is Nektar Therapeutics's Operating Income?
Operating Income
-135.2m
USD
Based on the financial report for Dec 31, 2023, Nektar Therapeutics's Operating Income amounts to -135.2m USD.
What is Nektar Therapeutics's Operating Income growth rate?
Operating Income CAGR 10Y
-1%
Over the last year, the Operating Income growth was 44%. The average annual Operating Income growth rates for Nektar Therapeutics have been 29% over the past three years , and -1% over the past ten years .